BG Medicine Inc. today announced a collaborative preclinical research study into the biochemical origins of muscle toxicity and
associated biomarkers with Mitsubishi Pharma Corporation (Osaka, Japan). BG Medicine (BGM) will apply their proprietary, integrated systems approach based on proteomics,
metabolomics and computational analyses to describe the molecular effects of selected
lipid lowering agents on skeletal muscle and to identify specific plasma biomarkers
of these effects. Mitsubishi Pharma Corporation will contribute transcript, clinical
chemistry and histopathology data to the effort.
Genetic Engineering News